Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety study of PiggyBac CAR-T cells targeting CD19 in relapsed or refractory B-cell ALL and lymphoma (Thailand)
TCTR20210818003Phase 1Recruiting
- Sponsor
- King Chulalongkorn Memorial Hospital
- Start
- Aug 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sino19 in B cell acute lymphoblastic leukemia (B-ALL) and malignant B-cell neoplasm, sponsored by King Chulalongkorn Memorial Hospital. Primary endpoint: Safety and tolerability of PiggyBac CD19 CAR-T cells. Started Aug 2021; status: recruiting.
02
Drugs
Sino19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)malignant B-cell neoplasm
Beyond the preview
Go deeper on TCTR20210818003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210818003.